Bortezomib as Therapy for Mixed Humoral and Cellular Rejection: Should It Be First Line?
Lee I, Constantinescu S, Gillespie A, Swami A, Birkenbach M, Leech S, Silva P, Karachristos A, Daller JA, Sifontis NM.
Clinical Transplants 2009, Chapter 41
Abstract
Bortezomib as Therapy for Mixed Humoral and Cellular Rejection: Should It Be First Line?
- Product Code: CT09_CH41
- Availability: In Stock
-
$5.00